Phuong Khanh Morrow's most recent trade in Lantheus Holdings Inc was a trade of 4,543 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Holdings Inc | Phuong Khanh Morrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 4,543 | 4,543 | - | - | Stock Option (right to buy) | |
| Lantheus Holdings Inc | Phuong Khanh Morrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 2,537 | 3,100 (0%) | 0% | 0 | Common Stock | |
| Lantheus Holdings Inc | Phuong Khanh Morrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 1,017 | 1,017 | - | - | Stock Option (right to buy) | |
| Lantheus Holdings Inc | Phuong Khanh Morrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 1,015 | 1,015 | - | - | Stock Option (right to buy) | |
| Lantheus Holdings Inc | Phuong Khanh Morrow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 563 | 563 (0%) | 0% | 0 | Common Stock | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 6,938 | 20,812 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 6,938 | 6,938 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.91 per share. | 23 May 2023 | 2,527 | 4,411 (0%) | 0% | 65.9 | 166,555 | Common Shares |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 44,620 | 44,620 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 22,000 | 22,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2022 | 9,380 | 9,380 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Phuong Khanh Morrow | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 27,750 | 27,750 | - | - | Restricted Stock Units |